B7-H3（CD276）是B7家族蛋白质的成员，是癌症进展的关键因素。此免疫检查点分子在肿瘤微环境中的肿瘤细胞和免疫细胞中表达。除了免疫检查点的功能外，B7-H3还与肿瘤细胞增殖、转移和治疗抵抗有关。此外，B7-H3在正常和肿瘤组织中的蛋白表达水平之间的显著差异表明用药物靶向B7-H3会导致癌症特异性毒性，最大程度地减少对健康细胞的伤害。这些特性使B7-H3成为癌症治疗的有希望的靶点。最近针对B7-H3的研究和药物开发取得了重要进展，这些新发现包括其参与细胞代谢重编程、癌症干细胞富集、衰老和肥胖，扩展了我们对这种分子的认识和理解，对未来的B7-H3靶向策略非常重要。在本综述中，我们简要讨论B7-H3在癌症发展中的生物学和功能。我们强调最新发现及其潜在机制，以反映B7-H3研究的最新进展。此外，我们还讨论了B-H3抑制剂在癌症药物开发中的新进展。©2023年，作者

B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer progression. This immune checkpoint molecule is selectively expressed in both tumor cells and immune cells within the tumor microenvironment. In addition to its immune checkpoint function, B7-H3 has been linked to tumor cell proliferation, metastasis, and therapeutic resistance. Furthermore, its drastic difference in protein expression levels between normal and tumor tissues suggests that targeting B7-H3 with drugs would lead to cancer-specific toxicity, minimizing harm to healthy cells. These properties make B7-H3 a promising target for cancer therapy.Recently, important advances in B7-H3 research and drug development have been reported, and these new findings, including its involvement in cellular metabolic reprograming, cancer stem cell enrichment, senescence and obesity, have expanded our knowledge and understanding of this molecule, which is important in guiding future strategies for targeting B7-H3. In this review, we briefly discuss the biology and function of B7-H3 in cancer development. We emphasize more on the latest findings and their underlying mechanisms to reflect the new advances in B7-H3 research. In addition, we discuss the new improvements of B-H3 inhibitors in cancer drug development.© 2023. The Author(s).